Web Exclusive: Finding Faith
March 16, 2010 – Kathy LaTour
Web Exclusive: Spirit-Sending Ceremony
March 16, 2010
Treatment Snapshot
March 16, 2010
Mutant Tissue Wanted
March 17, 2010 – Kathy LaTour
Today's Lesson: Cancer
March 17, 2010 – Bunmi Ishola
Camp Friendship
March 15, 2010 – Bunmi Ishola
Staging Takes a Leap
March 16, 2010 – Charlotte Huff
Now or Later?
March 16, 2010 – Charlotte Huff
Living with Lung Cancer
March 16, 2010 – Lori Monroe
A Good Night's Sleep
March 16, 2010 – Kathy LaTour
Pipeline
March 14, 2010 – Katy Human
Mediterranean Diet May Help Prevent Stomach Cancer
March 15, 2010 – Bunmi Ishola
Taking a Radiation 'Trip'
March 13, 2010 – Cyndi Fagot
Finding Meaning & Purpose
March 14, 2010 – Kathy LaTour
The Next Big Thing
March 15, 2010 – Katy Human
Preventive Vaccines: Triggering an Immune Response
March 15, 2010 – Katy Human
Creating a Plan to Get Moving
March 15, 2010 – Laura Beil
A How-To for the Social Media Beginner
March 15, 2010 – Karen Patterson
Cancer Vaccines No Longer a Long Shot
March 12, 2010 – Debu Tripathy, MD
Between Me and the River
March 03, 2010 – Kathy LaTour
Teens Helping Teens
March 02, 2010 – Bunmi Ishola
Q&A: CT Scans and Cancer Risk
March 15, 2010 – Len Lichtenfeld, MD
When You Need Information on el Cáncer
March 15, 2010 – Elizabeth Whittington
Following the Patient's Spiritual Lead
March 14, 2010 – Kathy LaTour
Go Fish
March 14, 2010 – Don Vaughan
Special Report
March 11, 2010 – Karen Patterson
Tingling Troubles
March 11, 2010 – Bunmi Ishola
Alongside My Wife
March 09, 2010 – Vaughn Smider, MD, PhD
Sleepless in Seattle, San Antonio & St. Louis
March 13, 2010 – Kathy LaTour
Welcomed Workout
March 04, 2010 – Laura Beil
Friends in Need
March 12, 2010 – Karen Patterson
Letters from Our Readers
March 01, 2010
More Than One Reason to Celebrate for Dexter Star
March 15, 2010 – Bunmi Ishola
New Jersey Legalizes Medical Marijuana
March 15, 2010 – Bunmi Ishola
Lung Overdue
March 13, 2010 – Charlotte Huff
Keeping the Faith
March 07, 2010 – Kathy LaTour
Getting Personal
March 04, 2010 – Katy Human
Web Exclusive: Finding Faith
March 16, 2010 – Kathy LaTour
Web Exclusive: Spirit-Sending Ceremony
March 16, 2010
Treatment Snapshot
March 16, 2010
Mutant Tissue Wanted
March 17, 2010 – Kathy LaTour
Today's Lesson: Cancer
March 17, 2010 – Bunmi Ishola
Camp Friendship
March 15, 2010 – Bunmi Ishola
Staging Takes a Leap
March 16, 2010 – Charlotte Huff
Currently Viewing
Now or Later?
March 16, 2010 – Charlotte Huff
A Good Night's Sleep
March 16, 2010 – Kathy LaTour
Pipeline
March 14, 2010 – Katy Human
Mediterranean Diet May Help Prevent Stomach Cancer
March 15, 2010 – Bunmi Ishola
Taking a Radiation 'Trip'
March 13, 2010 – Cyndi Fagot
Finding Meaning & Purpose
March 14, 2010 – Kathy LaTour
The Next Big Thing
March 15, 2010 – Katy Human
Preventive Vaccines: Triggering an Immune Response
March 15, 2010 – Katy Human
Creating a Plan to Get Moving
March 15, 2010 – Laura Beil
A How-To for the Social Media Beginner
March 15, 2010 – Karen Patterson
Cancer Vaccines No Longer a Long Shot
March 12, 2010 – Debu Tripathy, MD
Between Me and the River
March 03, 2010 – Kathy LaTour
Teens Helping Teens
March 02, 2010 – Bunmi Ishola
Q&A: CT Scans and Cancer Risk
March 15, 2010 – Len Lichtenfeld, MD
When You Need Information on el Cáncer
March 15, 2010 – Elizabeth Whittington
Following the Patient's Spiritual Lead
March 14, 2010 – Kathy LaTour
Go Fish
March 14, 2010 – Don Vaughan
Special Report
March 11, 2010 – Karen Patterson
Tingling Troubles
March 11, 2010 – Bunmi Ishola
Alongside My Wife
March 09, 2010 – Vaughn Smider, MD, PhD
Sleepless in Seattle, San Antonio & St. Louis
March 13, 2010 – Kathy LaTour
Welcomed Workout
March 04, 2010 – Laura Beil
Friends in Need
March 12, 2010 – Karen Patterson
Letters from Our Readers
March 01, 2010
More Than One Reason to Celebrate for Dexter Star
March 15, 2010 – Bunmi Ishola
New Jersey Legalizes Medical Marijuana
March 15, 2010 – Bunmi Ishola
Lung Overdue
March 13, 2010 – Charlotte Huff
Keeping the Faith
March 07, 2010 – Kathy LaTour
Getting Personal
March 04, 2010 – Katy Human

Now or Later?

Results of an Alimta study for maintenace therapy in lung cancer was presented at ASCO 2009.

BY Charlotte Huff
PUBLISHED March 16, 2010

Patients taking Alimta (pemetrexed) as a maintenance therapy for advanced non-squamous lung cancer lived a median of five months longer than patients taking a placebo, according to a randomized study reported at last year’s American Society of Clinical Oncology meeting. 

The results for Alimta, an intravenous medication, were one in a series of maintenance treatment studies presented at the meeting. Maintenance therapy actually reflects various approaches to prescribing drugs like Alimta, either immediately after chemotherapy ends, or after giving patients with advanced cancer a treatment break, says Nasser Hanna, MD, an associate professor at Indiana University Melvin and Bren Simon Cancer Center, who gave a presentation about maintenance therapy at ASCO. Second-line therapy typically refers to treatment given after the patient’s cancer progresses on initial therapy, whereas maintenance therapy is given after the cancer responds to first-line treatment.

At the ASCO meeting, researchers presented findings showing the median overall survival difference with Alimta was three months, 13.4 months versus 10.6 months for patients taking a placebo. But an analysis of a subset of 482 patients  diagnosed with non-squamous lung cancer showed they were the greatest beneficiaries. Their median survival was 15.5 months versus 10.3 months in the placebo group. “That’s the eye-popping part,” Hanna says. “That would be a survival gain that we are really not used to seeing [in lung cancer].”

FDA officials cited those results last July when they approved Alimta for maintenance treatment in patients with advanced non-squamous disease whose cancer hasn’t progressed following chemotherapy.

Research involving Tarceva (erlotinib) as maintenance therapy following chemotherapy was also presented at ASCO showing the EGFR inhibitor only slightly increased progression-free survival. In one study, progression-free survival reached a median of 12.3 weeks in patients on Tarceva, compared with 11.1 weeks for those taking placebo. Patients in the Tarceva group lived only slightly longer than patients in the placebo group, with median overall survival reaching 12 months and 11 months, respectively. 

In another trial, progression-free survival was slightly longer with a maintenance therapy combo of Avastin (bevacizumab) plus Tarceva, reaching 4.8 months, compared with 3.7 months for Avastin maintenance therapy alone. Patients in both arms received initial treatment with Avastin and chemotherapy.

Last December, an advisory panel to the FDA recommended against approval of Tarceva for maintenance. For lung cancer, the drug is only approved for use in advanced disease once chemotherapy fails.

These studies to date, as well as the Alimta analysis, haven’t provided a good sense of when maintenance treatment should begin, says Hanna, who worries about overtreating patients whose cancer might not advance right away and who could enjoy a respite from treatment-related side effects. In the Alimta study, serious side effects, including fatigue and neutropenia (a worrisome decrease in white blood cells), were more common in the Alimta group.

Ultimately, the weighing of risks and benefits is a personal decision between patient and physician, Hanna says. “Some patients will absolutely want breaks. Some patients will absolutely not want a break. It can really not be a one-size-fits-all.”  

Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the Lung Cancer CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In